NCT01437605View on ClinicalTrials.gov

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 11, 2011

Primary Completion Date

July 18, 2018

Study Completion Date

July 18, 2018

Conditions
Melanoma
Interventions
DRUG

MAGE-A3 ASCI injections without Poly IC:LC

MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description

DRUG

MAGE-A3 ASCI injections with Poly IC:LC

MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Oncovir, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01437605 - Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC | Biotech Hunter | Biotech Hunter